Zobrazeno 1 - 10
of 10
pro vyhledávání: '"MAYUKO YOSHIMURA"'
Autor:
Toshiaki Kume, Shota Nakagawa, Kazuma Murakami, Kazuhiro Irie, Mayuko Yoshimura, Takayuki Kondo, Haruhisa Inoue
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 4, p 1179 (2020)
International Journal of Molecular Sciences
Volume 21
Issue 4
International Journal of Molecular Sciences
Volume 21
Issue 4
Amyloid &beta
42 (A&beta
42), a causative agent of Alzheimer&rsquo
s disease (AD), is derived extracellularly from A&beta
precursor protein (APP) following the latter&rsquo
s cleavage by &beta
secretase, but not &alpha
42 (A&beta
42), a causative agent of Alzheimer&rsquo
s disease (AD), is derived extracellularly from A&beta
precursor protein (APP) following the latter&rsquo
s cleavage by &beta
secretase, but not &alpha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14714428c1711c089f2c9041fe0f56a1
https://www.mdpi.com/1422-0067/21/4/1179
https://www.mdpi.com/1422-0067/21/4/1179
Autor:
Mayuko Yoshimura
Publikováno v:
Annals of Japan Prosthodontic Society. 9:271-274
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1106d9d98b4eb2b20785c8130e088ad
https://doi.org/10.2186/ajps.9.271
https://doi.org/10.2186/ajps.9.271
Autor:
Satoru Tsuiki, Yoshihiro Iwata, Mayuko Yoshimura, Hiroshi Suzuki, Tatsuo Sakamaki, Takashi Kaneda, Taiga Fukuda, Misao Kawara
Publikováno v:
Journal of Dental Sleep Medicine. :77-79
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::466946756d5e66285c180f8ace602ae8
https://doi.org/10.15331/jdsm.6684
https://doi.org/10.15331/jdsm.6684
Autor:
Kazuya Ofuji, Keigo Saito, Toshiaki Yoshikawa, Tetsuya Nakatsura, Manami Shimomura, Yasunari Nakamoto, Yoshitaka Tada, Mayuko Yoshimura
Publikováno v:
International Journal of Oncology
Lung cancer is the leading cause of cancer‑related deaths worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a3b959a91801068ea2250d2d2586d14
https://doi.org/10.3892/ijo.2014.2787
https://doi.org/10.3892/ijo.2014.2787
Autor:
Mayuko Yoshimura, Hirofumi Shirakawa, Nobuhiro Tsuchiya, Yu Sawada, Masaru Konishi, Kazuya Ofuji, Yoshitaka Tada, Mari Takahashi, Toshiaki Yoshikawa, Naoto Gotohda, Daisuke Nobuoka, Tetsuya Nakatsura, Shiro Suzuki, Keigo Saito, Manami Shimomura, Yasunari Nakamoto, Shinichiro Takahashi
Publikováno v:
Oncotarget
// Kazuya Ofuji 1, 2, * , Keigo Saito 1, * , Shiro Suzuki 1 , Manami Shimomura 1 , Hirofumi Shirakawa 1 , Daisuke Nobuoka 1 , Yu Sawada 1 , Mayuko Yoshimura 1 , Nobuhiro Tsuchiya 1 , Mari Takahashi 1 , Toshiaki Yoshikawa 1 , Yoshitaka Tada 1 , Masaru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6730b888037c522c5195277a5243f019
https://pubmed.ncbi.nlm.nih.gov/28035063
https://pubmed.ncbi.nlm.nih.gov/28035063
Publikováno v:
Inflammation and Immunity in Cancer ISBN: 9784431553267
Glypican-3 (GPC3) is an onco-fetal antigen expressed in the placenta and embryonic liver and over-expressed in human hepatocellular carcinoma (HCC). We found that GPC3 is useful both as a novel tumor marker and as a target antigen for immunotherapy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24e3ee89eeb169016c073959045bb9ed
https://doi.org/10.1007/978-4-431-55327-4_11
https://doi.org/10.1007/978-4-431-55327-4_11
Publikováno v:
Oncology Reports
Cancer immunotherapy is a promising new approach to cancer treatment. It has been demonstrated that a high number of tumor-specific cytotoxic T cells (CTLs) is associated with increased disease-specific survival in lung cancer patients. Identificatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fb622cde2f6f1791b62d1335ed9f66
https://pubmed.ncbi.nlm.nih.gov/24842630
https://pubmed.ncbi.nlm.nih.gov/24842630
Autor:
Mari Takahashi, Kohei Nakachi, Junji Furuse, Naoto Gotohda, Masaru Konishi, Daisuke Nobuoka, Naoya Yamazaki, Yu Sawada, Shinichiro Takahashi, Yuichiro Kato, Masafumi Ikeda, Mayuko Yoshimura, Taira Kinoshita, Tetsuya Nakatsura, Katsuhiko Uesaka, Kazuya Ofuji, Kenji Yamao, Shoichi Mizuno, Tadatoshi Takayama, Itaru Endo, Toshiaki Yoshikawa, Nobuhiro Tsuchiya
Publikováno v:
Oncoimmunology
The recurrence rates of Hepatocellular carcinoma (HCC) are high, necessitating novel and effective adjuvant therapies. Therefore, we conducted a phase II study of glypican-3 (GPC3) peptide vaccine as an adjuvant therapy for HCC patients. Forty-one pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d61e291efde046d392dd50cca1cce7a
https://doi.org/10.1080/2162402x.2015.1129483
https://doi.org/10.1080/2162402x.2015.1129483
Autor:
Shoichi Mizuno, Toshiaki Yoshikawa, Nobuhiro Tsuchiya, Itaru Endo, Tetsuya Nakatsura, Mayuko Yoshimura, Yu Sawada, Kazuya Ofuji, Mari Takahashi, Daisuke Nobuoka
Publikováno v:
Cancer Research. 75:CT115-CT115
Background and purpose: In a phase I trial for advanced hepatocellular carcinoma (HCC), glypican-3(GPC3)-derived peptide vaccination was well-tolerated, and immune responses and antitumor efficacy were noted. The recurrence rates of HCC are still hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47c4192435dca7a41c7defb4a9b15996
https://doi.org/10.1158/1538-7445.am2015-ct115
https://doi.org/10.1158/1538-7445.am2015-ct115
Publikováno v:
Oncology Reports; 2014, Vol. 32 Issue 1, p33-39, 7p